AX Semantics, the easiest way to automate your content production

Content automation driven by NLG technology connects to the clinical study database and instantly generates HIPAA-compliant, auditable reports that help pharmaceutical companies meet regulatory requirements at a time when getting the right medications approved quickly is critical to global health.”

SAN FRANCISCO (PRWEB)
June 02, 2020

AX Semantics, an AI-powered, Natural Language Generation (NLG) market leader, today announced a new range of HIPAA-compliant content generation software for the pharmaceutical sector, which will allow pharmaceutical companies to generate regulatory Clinical Study Reports (CSRs) on medications up to 40% faster by automating 30% of writing the CSR.

“In addition to its effect on human lives and the economy, the coronavirus pandemic has exposed the hurdles pharmaceutical companies must overcome to get medication to patients. These processes are doubtless important to keep medications safe, but they also rely on outdated processes,“ said Saim Rolf Alkan, CEO and founder of AX Semantics. “Content automation driven by NLG technology connects to the clinical study database and instantly generates HIPAA-compliant, auditable reports that help pharmaceutical companies meet regulatory requirements at a time when getting the right medications and vaccines approved as expeditiously as possible is critical to ensure global public health.”

AX Semantics Upends the Status Quo.

The most challenging phase of bringing a drug to market is the human drug trial, or Phase III, during which time clinicians must write a CSR that describes the pharmacological impacts and trial outcomes. Typically, data collected from the human drug trials is gathered and medical writing teams manually compile the report, however, this outdated, onerous and time-consuming process can potentially delay life-saving medications from coming to market sooner and cost pharmaceutical companies millions. A capacity challenge also exists. Writing a CSR report typically takes several months to complete, which limits the number of CSRs a team of medical writers can produce annually. Some pharmaceutical companies have tried using templates to overcome the manual writing process challenge, however the templates have been found to be too complex and rigid for the different scenarios the CSR encompasses. For example, acceptable mortality rates can differ significantly depending on the drug that is being trialed: a drug that treats late stage cancer may have a mortality rate of 8%, which is acceptable, but a rate that high for a drug that treats a migraine headache is completely unacceptable. Templates cannot deal with these types of different scenarios, which severely limits their value.

AX Semantics content generation features for pharmaceutical and clinical study reports, include:

• NLG output based on structured data: allows users to easily configure projects to any structure and import tools and formats including JSON, CSV and Excel, and API for integration into existing systems like Oracle Databases without the need for complex IT projects;
• Topic and domain independent technology: all types of text can be generated, not just a limited set of topics — in up to 110 different languages;
• Easy-to-use interface with real-time, multi-user capability and workflows: multiple people can work on a project at the same time, allowing scaled project sizes, while retaining the ability to test and deploy; and
• Data Protection and Hybrid Cloud Availability: with certifiable processes and infrastructure that can be used for confidential information up to HIPAA/PHI level, and Sarbanes–Oxley/MARisk certifiable processes.

Named one of the world’s top five providers of natural language generation platforms by Gartner, and a top emerging company in the NLG market by Forrester, AX Semantics offers a subscription-based service, with fees between $279 and $1699 per month for pharmaceutical companies. A managed service that creates the CSR reporting is also available on top of the self-service platform for new product development purposes and customers that don’t have qualified in-house resources by utilizing the global Network of AX Semantics’ Managed Service Providers like hmmh (Serviceplan Group), Deloitte and uNaice. An industry first, this fully managed project is available at fixed flat rates with a pricing from $7,999 to $18,999, further reducing ramp up time for the project and minimizing the needed investments. The software is 100% SaaS – everything is available via a web browser, with no programming or IT departments required. Self-service with integrated e-learning allows customers to start automating text within 48 hours, often less. Learn more at sales@ax-semantics.com.

About AX Semantics

AX Semantics is an AI-powered, natural language generation (NLG) software company built to address today’s biggest content generation challenges. Our sophisticated SaaS-based solution effortlessly creates vast quantities of content at scale – to tackle time-intensive financial reporting and regulatory requirements filings, automate laborious pharmaceutical Clinical Study Reports, fill a news section with earnings reports, sports scores or weather reports, generate 1000s of unique product descriptions for e-commerce brands, produce social media content, and more. We make automated content generation — in more than 110 languages, in a manner of minutes — a reality for customers of all sizes within the finance, pharmaceutical, e-commerce, business and media publishing sectors.

Headquartered in Stuttgart, Germany with an additional office in Sunnyvale, California, AX Semantics is a privately-held company backed by Airbridge Equity Partners. Follow us on social at Twitter, LinkedIn, Facebook and Instagram, or learn more at https://en.ax-semantics.com.

All trademarks contained herein are the property of their respective owners.

Share article on social media or email:

SAN DIEGO (PRWEB)
June 02, 2020

Unlike a mosquito bite where people know immediately if they have been bitten, a tick bite may go undetected; and one of the challenges with Lyme disease is that symptoms may not appear for two to six weeks. That makes it critically important to take steps to avoid catching the disease and to know its warning signs so treatment can begin early when it is most effective.

“While not all deer ticks cause Lyme disease, it is still smart to avoid areas where deer ticks live, especially wooded, bushy areas with long grass,” said Sean McCloy, M.D., a family medicine physician with an expertise in Lyme disease at the Integrative Health Center of Maine. “You can decrease your risk of getting Lyme disease with some simple precautions, such as wearing shoes, long pants tucked into your socks, a long-sleeved shirt, a hat and gloves. And after spending time in vulnerable areas you should always check your clothing, yourself, your children and your pets for ticks; and remove any that you find as soon as possible with tweezers. Only a minority of tick bites leads to Lyme disease; but the longer the tick remains attached to your skin, the greater your risk of getting the disease.”

For those who are bitten by an infected tick, early warning signs include fever, headache, fatigue, joint pain, swollen lymph nodes, weakness in the limbs and a characteristic skin rash often in a bull’s-eye pattern. If untreated, new symptoms could include neurological problems and, though less common, heart problems (such as an irregular heartbeat), eye inflammation, liver inflammation and severe fatigue.

“If you think you’ve been bitten and have signs and symptoms of Lyme disease—particularly if you live in an area where Lyme disease is prevalent—it is critical to get tested as treatment is more effective if begun early,” said Robert Dracker, M.D., chairman of the heart, lung and cancer committee for the Medical Society of New York and medical director of Summerwood Pediatrics and Infusacare Medical Services in New York. “Fortunately, new tests are available that are easy to administer and provide results faster than ever.”

Leading the way in Lyme disease testing is the innovative Sofia 2 Lyme FIA test. This in-office test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. The test was developed by Quidel, a California-based diagnostic healthcare manufacturer and one of the nation’s leaders in developing rapid diagnostic health solutions.

“Given that the vast majority of patients tested are negative, getting results quickly will mean discernable peace of mind and remove a significant weight off a person’s shoulders,” said Dr. Dracker. “Not having to wait days for test results allows physicians and nurse practitioners to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative.”

Patients seeking more information are encouraged to contact their private physician to find out more about the availability of this innovative new test in their area. More information on Quidel may be obtained at quidel.com.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions including not only Lyme disease but, among others, influenza, respiratory syncytial virus, strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel, visit quidel.com.

Share article on social media or email:

The entire Aniara line is available for purchase at http://www.aniara.com

WEST CHESTER, Ohio (PRWEB)
June 02, 2020

Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today’s highest standards for product quality and cost-efficient delivery.

Xenometrix products are made for use in molecular pharmacology, early stages of drug discovery, screening of chemical, cosmetic, alimentary, or agrochemical compounds, and for testing environmental water, soil, air, or effluents.

Rapid MicroNucleus MoA is designed for an easier and reliable detection of all repeated human centromere sequences with a high efficiency and strong signal. Rapid MicroNucleus MoA permits the user identify the nature of substances (or exposure) (Aneugens and Clastogens) in addition to the scoring of micronuclei in line with TG OECD 487.

These kits provide all key reagents needed to perform fluorescence in situ hybridization for the detection of centromere sequences by microscopy

AM020 Rapid MicroNucleus MoA (20 tests) click here for more information

AM100 Rapid MicroNucleus MoA (100 tests) click here for more information

Aniara also offers a full range of Ames kits including Ames MPF and Ames II click here for more information

The entire Aniara product line is available for purchase at http://www.aniara.com. The Company distributes products in North America, Central America, South America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

Share article on social media or email:

Charles Lickfold, Senior Vice President, Chief Information Officer, Catalent

We welcome Charlie to Catalent and look forward to gaining the benefit of his experience and expertise. I also want to thank John for his leadership and contribution to the company over the last seven years, and wish him all the best in his retirement.

SOMERSET, N.J. (PRWEB)
June 02, 2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the appointment of Charles Lickfold as Senior Vice President, Chief Information Officer. Mr. Lickfold succeeds John McGill, who, following a period of transition, plans to retire in September 2020.

Mr. Lickfold will report to Alessandro Maselli, the company’s President and Chief Operating Officer, and assume responsibility for Catalent’s global IT services and technology, overseeing all aspects of information technology service and functions at the company’s global network of facilities. In addition, Mr. Lickfold will lead Catalent’s continuing digital transformation and automation strategy while ensuring the most rigorous data integrity standards are met.

With more than 20 years of experience in digital and information technology, Mr. Lickfold has demonstrated significant IT leadership in the pharmaceutical services industry throughout his career. Prior to joining Catalent, he held numerous leadership positions, including Chief Information Officer at Alcami, Avara Pharmaceutical Services, and Gilbarco Veeder-Root. He also served as Vice President and Head of IT for Patheon. His depth of experience in both applications and infrastructure across diverse IT environments includes extensive work in the areas of IT transformation, corporate mergers and acquisitions, and business change programs. Mr. Lickfold began his career as a management consultant in the life sciences practice of Ernst & Young LLP after earning his bachelor’s degree in computer science from the University of Kentucky’s College of Engineering.

“At the heart of any company is its function to interact digitally, communicate globally, and protect internal systems to ensure the integrity of the business. In recent months, the ability to work remotely has been put to the test, and our investments in information technology have been central to Catalent’s success in continuing to function efficiently,” commented Mr. Maselli. “We welcome Charlie to Catalent and look forward to gaining the benefit of his experience and expertise. I also want to thank John for his leadership and contribution to the company over the last seven years, and wish him all the best in his retirement.”

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Drs. Kenneth and Jonathan Nash Offer Gentle Laser Dentistry in Vicksburg, MS

The laser is kinder to the dental tissues. Often times, we can do procedures with the dental laser where we don’t need dental anesthesia.

VICKSBURG, Miss. (PRWEB)
June 02, 2020

The experienced dentists at Nash Family Dentistry, Drs. Kenneth and Jonathan Nash, now welcome existing and new patients to receive state-of-the-art laser dentistry in Vicksburg, MS. Laser dentistry can be used to treat a variety of dental concerns, both functional and aesthetic, with minimal discomfort and less time in the dental office. The practice features BIOLASE® WaterLase iPlus® and Epic dental lasers for modern treatments.

“The laser is kinder to the dental tissues,” says Dr. Kenneth Nash. “Often times, we can do procedures with the dental laser where we don’t need dental anesthesia. We can use the dental laser to do more conservative procedures than with a drill. Because we don’t have to wait on anesthesia and we can be more conservative, we can be more efficient for our patients in the dental chair.”

A dental laser is a modern dental tool that can replace scalpels and blades for a multitude of procedures. Laser dentistry utilizes gentle laser light to target the disease and remove it with minimal discomfort, bleeding and time. It often allows Drs. Nash to be more precise as well, meaning less harm happens to healthy tissue and surrounding teeth. Treatments that can benefit from laser dentistry include:

• Gum disease care
• Gum recontouring
• Gingivectomies
• TMJ treatment
• Periodontal maintenance

Dental lasers have proven efficient for the treatment of gum disease as they can offer precise, gentle care and perform in a timely manner. When using one of the BIOLASE lasers for gum disease, Drs. Nash will gently eradicate the infected tissue from the gums, leaving healthy tissue unharmed. Because of the quick nature of the procedure, multiple areas of gum disease can be cleansed from the mouth at once, meaning patients will not have to return for multiple procedures. The lasers are also precise enough to be able to perform periodontal maintenance on the mouth after gum disease has been treated. This treatment includes a deep cleaning of teeth, gums and the area between the two and is often recommended every two to three months after eradicating gum disease.

Nash Family Dentistry specializes in advanced technology for many dental treatments because they believe that staying on top of technology gives patients a better overall dental experience and allows the dentists to provide more precise, gentle care. In addition to modern technology, the practice also offers full-service dental treatments, including dental implants, full mouth reconstruction and cosmetic dentistry as well.

Those interested in receiving leading care with a gentle approach are encouraged to book an appointment for laser dentistry in Vicksburg, MS at Nash Family Dentistry. Appointments can be made by visiting http://www.vicksburgdentist.com or calling 601-634-1812.

About the Dentists

Nash Family Dentistry is a general practice offering personalized dental care for patients in Vicksburg, MS. Dr. Kenneth Nash, Dr. Jonathan Nash and their team provide patients with the latest in dental technology in a comfortable and welcoming environment. Drs. Nash offer a variety of services including laser dentistry, dental implants, and cosmetic dentistry services, among others. To learn more about the services offered at Nash Family Dentistry please visit the website at http://www.vicksburgdentist.com or call 601-634-1812 to schedule an appointment.

Share article on social media or email: